Argyrophilic grain disease

Brain

Volumn 131, Issue 6, 2008, Pages 1416-1432

  Ferrer, Isidro ^a,b,d   Santpere, Gabriel ^a   Van Leeuwen, Fred W ^c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Alzheimer's disease; Argyrophilic grain disease; GSK 3 ; Mutant ubiquitin; Oxidative stress; P62; Stress kinases; Tau; Ubiquitin

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; GLYCOGEN SYNTHASE KINASE 3BETA; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MUTANT PROTEIN; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; PROTEIN P62; PROTEIN TAU 4R; TAU PROTEIN; THROMBIN; UBIQUITIN;

AGING; ALZHEIMER DISEASE; ARGYROPHILIC GRAIN DISEASE; ASTROCYTE; CLINICAL FEATURE; COILED BODY; CONFOCAL MICROSCOPY; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DISEASE CLASSIFICATION; ELECTRON MICROSCOPY; GEL ELECTROPHORESIS; GLIA CELL; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OLIGODENDROGLIA; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SILVER STAINING; TAUOPATHY; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; DEMENTIA; HUMANS; MUTATION; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; OXIDATIVE STRESS; TAU PROTEINS; UBIQUITIN;

EID: 44949150103     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awm305     Document Type: Review

References (153)

1. Abraha A, Ghoshal N, Gamblin TC, Cryns V, Berry RW, Kuret J, et al. C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 2000; 113: 3737-45.
2. Alafuzoff I, Pikkarainen M, Al-Sarraj S, Arzberger T, Bell J, Bodi I, et al. Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol 2006; 65: 740-57.
3. Arai T, Guo GP, McGeer PL. Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. J Biol Chem 2005; 280: 5145-53.
4. Arai T, Miklossy J, Klegeris A, Guo JP, McGeer PL. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol 2006; 65: 19-25.
5. Bancher C, Brunner C, Lassman H, Budka H, Jellinger K, Wiche G, et al. Accumulation of abnormally phosphorylated tau precedes tau formation of neurofibrillary tangles in Alzheimer's disease. Brain Res 1989; 477: 90-9.
6. Beach TG, Sue L, Scott S, Layne K, Newell A, Walker D, et al. Hippocampal sclerosis dementia with tauopathy. Brain Pathol 2003; 13: 263-78.
7. Botchler M, Ditzel Groll M, Hartmann C, Huber R. The proteasome. Annu Rev Biophys Biomol Struct 1999; 28: 295-317.
8. Botez G, Probst A, Ipsen S, Tolnay M. Astrocytes expressing hyperphosphorylated tau protein without glial fibrillary tangles in argyrophilic grain disease. Acta Neuropathol 1999; 98: 251-6.
9. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404.
10. Braak H, Braak E. Argyrophylic grains: characteristic pathology of cerebral cortex in cases of adult-onset dementia without Alzheimer changes. Neurosci Lett 1987; 76: 124-7.
11. Braak H, Braak E. Cortical and subcortical argyrophylic grains characterize a disease associated with adult onset dementia. Neuropathol Appl Neurobiol 1989; 15: 13-26.
12. Braak H, Braak E. Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J Neural Transm 1998; 105: 801-19.
13. Braak H, Braak E. Temporal sequence of Alzheimer's disease-related pathology. In: Peters A and Morrison JH, editors. Cerebral Cortex Vol 14: Neurodegenerative and Age-related Changes in Structure and Function of Cerebral Cortex. New York, Boston, Dordrecht, London, Moscow: Kluwer Academic/Plenum Press; 1999. p. 475-512.
14. Braak H, Braak E, Mandelkow EM. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 1994; 87: 554-67.
15. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
16. Buée-Scherrer V, Goedert M. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett 2002; 515: 151-4.
17. Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 2006a; 545: 39-50.
18. Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WN, Klein JB, et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 2006b; 22: 223-32.
19. Cairns NJ, Bigio EH, MacKenzie IRA, Neumann M, Lee VMY, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobal degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol 2007; 114: 5-22.
20. Cecarini V, Ding Q, Keller JN. Oxidative inactivation of the proteasome in Alzheimer's disease. Free Radic Res 2007; 41: 673-80.
21. Cente M, Filipcik P, Pevalova M, Novak M. Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy. Eur J Neurosci 2006; 24: 1085-90.
22. Chin SM, Goldman EJ. Glial inclusions in the CNS degenerative diseases. J Neuropathol Exp Neurol 1996; 55: 499-508.
23. Cras P, Perry G. Dementia with argyrophilic grains. Ann Neurol 1991; 30: 853-4.
24. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A. Protein carbonylation, cellular dysfunction and disease progression. J Cell Mol Med 2006; 10: 389-406.
25. Davis DG, Ross GW, Petrovich H, White LR, Hardman JM, Nelson JS, et al. Quantitation of argyrophilic grains in hippocampal CA1 of aged Japanese-American men. J Neuropathol Exp Neurol 1997; 56: 587.
26. de Pril R, Fischer DF, Maat-Schieman ML, Hobo B, De Vos RA, Brunt ER, et al. Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum Mol Genet 2004; 13: 1803-13.
27. De Vos RAI, Jansen ENH, Wesseling P, Braak H. Parkinson's disease and dementia with argyrophilic grains. Neuropathol Appl Neurobiol 1996; 22 (Suppl 1): 75.
28. Ding ZT, Wang Y, Jiang YP, Yoshida M, Mimuro M, Inagaki T, et al. Argyrophilic grain disease: frequency and neuropathology in centenarians. Acta Neuropathol 2006; 111: 320-8.
29. Fasulo L, Ugolini G, Visintin M, Bradbury A, Brancolini C, Verzillo V, et al. The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. J Neurochem 2000; 75: 624-33.
30. Ferrer I. El método de Golgi en neuropatología humana. In: Cruz-Sanchez F, editor. Neuropatología. Madrid: Edimsa; 2000. p. 113-6.
31. Ferrer I. Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies, and APP transgenic mice. Neurotox Res 2004; 6: 469-75.
32. Ferrer I, Aymami A, Rovira A, Grau Veciana JM. Growth of abnormal neurites in Alzheimer's disease. A study with the Golgi method. Acta Neuropathol 1983; 59: 167-70.
33. Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 2002a; 104: 583-91.
34. Ferrer I, Barrachina M, Puig B. Anti-tau phosphospecific Ser262 antibody recognizes a variety of abnormal hyper-phosphorylated tau deposits in tauopathies including Pick's disease and argyrophilic grains. Acta Neuropathol 2002b; 104: 658-64.
35. Ferrer I, Barrachina M, Tolnay M, Rey MJ, Vidal N, Carmona M, et al. Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease. Brain Pathol 2003; 13: 62-78.
36. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, et al. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2005; 2: 3-18.
37. Ferrer I, Guionnet N, Cruz-Sanchez F, Tuñon T. Neuronal alterations in patients with dementia: a Golgi study on biopsy samples. Neurosci Lett 1990; 114: 11-6.
38. Ferrer I, Hernandez I, Boada M, Llorente A, Rey MJ, Cardozo A, et al. Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies. Acta Neuropathol 2003; 106: 419-35.
39. Fischer DF, De Vos RA, Van DR, De Vrij FM, Proper EA, Sonnemans MA, et al. Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. FASEB J 2003; 17: 2014-24.
40. Fujino Y, Delucia MW, Davies P, Dickson DW. Ballooned neurons in the limbic lobe are associated with Alzheimer type pathology and lack diagnostic specificity. Neuropathol Appl Neurobiol 2004; 30: 676-82.
41. Fujino Y, Wang DS, Thomas N, Espinoza M, Davies P, Dickson DW. Increased frequency of argyrophilic grain disease in Alzheimer disease with 4R tau-specific immunohistochemistry. J Neuropathol Exp Neurol 2005; 64: 209-14.
42. Geetha T, Wooten MW. Structure and functional properties of the ubiquitin binding protein p62. FEBS Lett 2002; 512: 19-24.
43. Ghebremedin E, Schultz C, Botez G, Rub U, Sassin I, Braak E, et al. Argyrophilic grain disease is associated with apolipoprotein E epsilon 2 allele. Acta Neuropathol 1998; 96: 222-4.
44. Ghebremedin E, Schultz C, Thal DR, Del Tredici K, Rueb U, Braak H. Genetic association of argyrophilic grain disease with polymorphisms in alpha-2 macroglobulin and low-density lipoprotein receptor-related protein genes. Neuropathol Appl Neurobiol 2002; 28: 308-13.
45. Ghosh JG, Houck SA, Clark JI. Interactive domains in the molecular chaperone human αB-crystallin modulate microtubule assembly and disassembly. PLoS ONE 2007a; 2: e498.
46. Ghosh JG, Houck SA, Clark JI. Interactive sequences in the stress protein and molecular chaperone human αB-crystallin recognize and modulate the assembly of filaments. In J Biochem Cell Biol 2007b; 39: 1804-15.
47. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
48. Goedert M, Hasegawa M, Jakes R, Lawler S, Cuenda A, Cohen P. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett 1997; 409: 57-62.
49. Goedert M, Spillantini MG, Davies SW. Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol 1998; 8: 619-32.
50. Goedert M, Spillanini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989; 8: 393-9.
51. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 1992; 147: 58-62.
52. Herschko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-79.
53. Himmler A, Drechsel D, Kirschner MW, Martin DW. Tau consists of a set of proteins with repeat C-terminal microtubule-binding domains and variable N-terminal domains. Mol Cell Biol 1989; 9: 1381-8.
54. Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004; 56: 399-406.
55. Ikeda K, Akiyama H, Arai T, Matsushita M, Tsuchiya K, Miyazaki H. Clinical aspects of argyrophilic grain disease. Clin Neuropathol 2000; 19: 278-84.
56. Ikeda K, Akiyama H, Arai T, Nishima T. Glial tau pathology in neurodegenerative diseases: their nature and comparison with neuronal tangles. Neurobiol Dis 1998; 19: 85-91.
57. Ikeda K, Akiyama H, Kondo H, Haga C. A study of dementia with argyrophilic grains. Possible cytoskeletal abnormality in dendrospinal portion of neurons and oligodendroglia. Acta Neuropathol 1995; 89: 409-14.
58. Ishihara K, Araki S, Ihori N, Shiota J, Kawamura M, Yoshida M, et al. Argyrophilic grain disease presenting with frontotemporal dementia: a neuropsychological and pathological study of an autopsied case with presenile onset. Neuropathology 2005; 25: 165-70.
59. Ishizawa T, Ko LW, Cookson N, Davias P, Espinoza M, Dickson DW. Selective neurofibrillary degeneration of the hippocampal CA2 sector is associated with four-repeat tauopathies. J Neuropathol Exp Neurol 2002; 61: 1040-7.
60. Itagaki S, Mc Geer PL, Akiyama H, Beattie BL, Walker DG, Moore GR, et al. A case of adult-onset dementia with argyrophilic grains. Ann Neurol 1989; 26: 685-9.
61. Jellinger KA. Dementia with grains (argyrophilic grain disease). Brain Pathol 1998; 8: 377-86.
62. Jellinger KA, Bancher C. Senile dementia with tangles (tangle predominant form of senile dementia). Brain Pathol 1998; 8: 367-76.
63. Jenkins SM, Zinnerman M, Garner C, Johnson GV. Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem J 2000; 345: 263-70.
64. Jicha GA, Petersen RC, Knopman DS, Boeve BF, Smith GE, Geda YE, et al. Argyrophilic grain disease in demented subjects presenting initially with amnestic mild cognitive impairment. J Neuropathol Exp Neurol 2006; 65: 602-9.
65. Josephs KA, Whitwell JL, Parisi JE, Knopman DS, Boeve BF, Geda YE, et al. Argyrophilic grai: a distinct disease or an additive pathology? Neurobiol Aging 2006 Dec 22 [Epub ahead of print].
66. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 2003; 85: 115-22.
67. Kiwashima T, Katsumi D, Iwaki T. Argyrophilic grains in late-onset Creutzfeldt-Jakob diseased brains. Pathol Internat 1999; 49: 369-73.
68. Klos KJ, Josephs KA, Parisi JE, Dickson DW. Alpha-synuclein immunohistochemistry in two cases of co-ocurring idiopathic Parkinson's disease and motor neuron disease. Mov Disord 2005; 20: 1515-20.
69. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003; 62: 1087-95.
70. Komori T. Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol 1999; 9: 663-79.
71. Kovacks GK, Pittman A, Revesz T, Luk C, Lees A, et al. MAPT S305I mutation: implications for argyrophilic grain disease. Acta Neuropathol 2007; Dec 8 [Epub ahead of print].
72. Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 2003; 62: 1241-53.
73. Kuusisto E, Salminen A, Alafuzoff I. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 2001; 12: 2085-90.
74. Kuusisto E, Salminen A, Alafuzoff I. Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: possible role in tangle formation. Neuropathol Appl Neurobiol 2002; 28: 228-37.
75. ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 17810-4.
76. Layfield R, Cavey JR, Lowe J. Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res Rev 2003; 2: 343-56.
77. Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3β in Alzheimer's disease and accumulation in argyrophilic grains in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 2007; 33: 43-55.
78. Liang TW, Forman MS, Duda JE, McCluskey L, Trojanowski JQ, Siderowf A. Multiple pathologies in a patient with a progressive neurodegenerative syndrome. J Neurol Neurosurg Psychiatry 2005; 76: 252-5.
79. Lindsten K, De Vrij FM, Verhoef LG, Fischer DF, van Leeuwen FW, Hol EM, et al. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J Cell Biol 2002; 157: 417-27.
80. Lovestone S, Reynolds CH. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 1997; 78: 309-24.
81. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, Vandenheede JR, et al. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett 1992; 314: 315-21.
82. Martinez-Lage M, Muñoz DG. Prevalence and disease association of argyrophilic grains of Braak. J Neuropathol Exp Neurol 1997; 56: 157-64.
83. Masliah E, Hansen LA, Quijata S, De Teresa R, Alford M, Kauss J, et al. Late onset dementia with argyrophilic grains and subcortical tangles or atypical progressive supranuclear palsy. Ann Neurol 1991; 29: 389-96.
84. Maurage CA, Sergeant N, Schraen-Maschke SS, Lebert F, Ruchoux MM, Sablonnière B, et al. Diffuse form of argyrophilic grain disease: a new variant of four-repeat tauopathy different from limbic argyrophilic grain disease. Acta Neuropathol 2003; 106: 575-83.
85. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnostic [Diagnostics? Diagnosis?] and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-72.
86. Miserez AR, Clavaguera F, Monsch AU, Probst A, Tolnay M. Argyrophilic grain disease: molecular genetic difference to other four-repeat tauopathies. Acta Neuropathol 2003; 106: 363-6.
87. Moreira PI, Honda K, Liu Q, Santos MS, Oliveira CR, Aliev G, et al. Oxidative stress: the old enemy in Alzheimer's disease. Curr Alzheimer Res 2005; 2: 403-8.
88. Mudher AK, Yee B, Smith AD, Perry VH. Deafferentation of the hippocampus results in the induction of AT8 positive 'granules' in the rat. Neurosci Lett 2001; 301: 5-8.
89. Nakaso K, Yoshimoto Y, Nakano T, Takeshima T, Fukuhara Y, Yasui K, et al. Transcriptional activation of p62/A170/ZIP during the formation of the aggregates: possible mechanisms and the role in Lewy body formation in Parkinson's disease. Brain Res 2004; 1012: 42-51.
90. Novak M, Jakes R, Edwards PC, Milstein C, Wischik CM. Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. Proc Natl Acad Sci USA 1991; 88: 5837-41.
91. Novak M, Kabat J, Wischik CM. Molecular characterisation of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J 1993; 12: 365-70.
92. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006; 65: 631-41.
93. Ohto-Fujita E, Fujita Y, Atomi Y. Analysis of the αB-crystallin domain responsible for inhibiting tubulin aggregation. Cell Stress Chaperones 2007; 12: 163-71.
94. Pamplona R, Dalfó E, Ayala V, Bellmunt J, Prat J, Ferrer I, et al. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 2005; 280: 21522-30.
95. Perez-Buira S, Barrachina M, Rodriguez A, Albasanz JL, Martin M, Ferrer I. Expression levels of adenosine receptors in hippocampus and frontal cortex in argyrophilic grain disease. Neurosci Lett 2007; 423: 194-9.
96. Petersen RB, Nunomura A, Lee HG, Casadesus G, Perry G, Smith MA, et al. Signal transduction cascades associated with oxidative stressing Alzheimer's disease. J Alzheimers Dis 2007; 11: 143-52.
97. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63: 665-72.
98. Popescu A, Lippa CF, Lee VM, Trojanowski JQ. Lewy bodies in the amygdala: increase of α-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol 2004; 61: 1915-9.
99. Probst A, Basler V, Bron B, Ulrich J. Neuritic plaques in senile dementia of Alzheimer's type: a Golgi analysis in the hippocampal region. Brain Res 1983; 59: 167-70.
100. Probst A, Taylor KI, Tolnay M. Hippocampal sclerosis dementia: a reappraisal. Acta Neuropathol 2007; 114: 335-45.
101. Puig B, Ferrer I, Ludueña RF, Avila J. BetaII-tubulin and phospho-tau aggregates in Alzheimer's disease and Pick's disease. J Alzheimers Dis 2005; 7: 213-20.
102. Puig B, Gómez-Isla T, Ribé E, Cuadrado M, Torrejón-Escribano B, Dalfó E, et al. Expression of stress-activated kinase c-Jun N-terminal kinase (SAPK/JNK-P) and p38 (p38-P), and tau hyperphosphorylation in neurites surrounding βA plaques in APP Tg2576 mice. Neuropathol. Appl Neurobiol 2004; 30: 491-502.
103. Quintana C, Bellefgih S, Laval JY, Guerkin-Kern JL, Wu TD, Avila J, et al. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol 2006; 153: 42-54.
104. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and p38, and glycogen synthase kinase-3b. J Neurochem 2000; 74: 1587-95.
105. Reynolds CH, Nebreda AR, Gibb GM, Utton MA, Anderton BH. Reactivating kinase/p38 phosphorylates tau protein in vitro. J Neurochem 1997a; 69: 191-8.
106. Reynolds CH, Utton MA, Gibb GM, Yates A, Anderton BH. Stress-activated protein kinase/c-Jun N-terminal kinase phosphorylates tau protein. J Neurochem 1997b; 68: 1736-44.
107. Rippon GA, Boeve BF, Parisi JE, Dickson DW, Ivnik RI, Jack CR, et al. Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimer's disease pathology. Neurocase 2005; 11: 204-11.
108. Saito Y, Nakahara K, Yamanouchi H, Murayama S. Severe involvement of ambient gyrus in dementia with grains. J Neuropathol Exp Neurol 2002; 61: 789-96.
109. Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, et al. Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 2004; 63: 911-8.
110. Santpere G, Puig B, Ferrer I. Low molecular weight species of tau in Alzheimer's disease are dependent on tau phosphorylation sites but not on delayed post-mortem delay in tissue processing. Neurosci Lett 2006; 399: 106-10.
111. Scheibel AB, Tomiyasu U. Dendritic sprouting in Alzheimer's senile dementia. Expl Neurol 1978; 60: 1-8.
112. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498: 99-111.
113. Schultz C, Koppers D, Sassin I, Braak E, Braak H. Cytoskeletal alterations in the human tuberal hypothalamus related to argyrophilic grain disease. Acta Neuropathol 1998; 96: 596-602.
114. Scott IS, Lowe JS. The ubiquitin-binding protein p62 identifies argyrophylic grain pathology with greater sensitivity than conventional silver stains. Acta Neuropathol 2007; 113: 417-20.
115. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 2004; 24: 8055-68.
116. Seno H, Kobayashi S, Inagaki T, Yamamori C, Miyaoka T, Horiguchi J, et al. Parkinson's disease associated with argyrophilic grains clinically resembling progressive supranuclear palsy: an autopsy case. J Neurol Sci 2000; 178: 70-4.
117. Singh BN, Rao KS, Ramakrishna T, Rangaraj N, Rao ChM. Association of αB-crystallin, a small heat shock protein, with actin: role in modulating actin filament dynamics in vivo. J Mol Biol 2007; 366: 756-67.
118. Skrabana R, Kontsek P, Mederlyova A, Iqbal K, Novak M. Folding of Alzheimer's core PHF subunit revealed by monoclonal antibody 423. FEBS Lett 2004; 568: 178-82.
119. Spillantini MG, Tolnay M, Love S, Goedert M. Microtubule-associated protein tau, heparin sulphate and synuclein in several neurodegenerative diseases with dementia. Acta Neuropathol 1999; 97: 585-94.
120. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, et al. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 2006a; 27: 1564-76.
121. Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanisms of neurodegeneration from redox proteomics. Antioxid Redox Signal 2006b; 8: 2021-37.
122. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, et al. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 2006c; 22: 76-87.
123. Thal DR, Schultz C, Botez G, Del Tedici K, Mrak RE, Griffin WST, et al. The impact or agyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology. Neuropathol Appl Neurobiol 2005; 31: 270-9.
124. Togo T, Cookson N, Dickson D. Argyrophilic grain disease: neuropathology, frequency in a dementia brain bank and lack of relationship with apolipoprotein E. Brain Pathol 2002; 12: 45-52.
125. Togo T, Dickson DW. Ballooned neurons in progressive supranuclear palsy are usually due to concurrent argyrophilic grain disease. Acta Neuropathol 2002; 104: 53-6.
126. Togo T, Isojima D, Akatsu H, Suzuki K, Uchikado H, Katsuse O, et al. Clinical features of argyrophilic grain disease. A retrospective survey of cases with neuropsychiatric symptoms. Am J Geriatr Psychiatry 2005; 13: 1083-91.
127. Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, Hutton M, et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropath Exp Neurol 2002; 61: 547-56.
128. Tolnay M, Calhoum M, Pham HC, Egensperger R, Probst A. Low amyloid (Aβ) plaque load and relative predominance of diffuse plaques distinguish argyrophilic grain disease from Alzheimer's disease. Neuropathol Appl Neurobiol 1999; 25: 295-305.
129. Tolnay M, Clavaguera F. Argyrophilic grain disease: a late-onset dementia with distinctive features among tauopathies. Neuropathology 2004; 24: 269-83.
130. Tolnay M, Ghebremedhin E, Probst A, Braak H. Argyrophilic grain disease. In: Dickson D, editor. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropath Press; 2003. p. 132-6.
131. Tolnay M, Mistl C, Ipsen S, Probst A. Argyrophilic grains of braak: occurrence in dendrites of neurons containing phosphorylated tau protein. Neuropathol Appl Neurobiol 1998; 24: 53-9.
132. Tolnay M, Monsch AU, Probst A. Argyrophilic grain disease. A frequent dementing disorder in aged patients. Adv Exp Med Biol 2001; 487: 39-58.
133. Tolnay M, Probst A. Ballooned neurons expressing αB-crystallin as a constant feature of the amygdala in argyrophilic grain disease. Neurosci Lett 1998; 246: 165-8.
134. Tolnay M, Probst A. Review: tau protein pathology in Alzheimer's disease and related disorders. Neuropathol Appl Neurobiol 1999; 25: 171-87.
135. Tolnay M, Probst A, Monsch AU, Staehlin HB, Egensperger R. Apolipoprotein E allele frequencies in argyrophilic grain disease. Acta Neuropathol 1998; 96: 225-7.
136. Tolnay M, Sergeant N, Ghestem A, Chalbot S, de Vos RA, Jansen Steur EN, et al. Argyrophilic grain disease and Alzheimer disease are distinguished by their different distribution of tau protein isoforms. Acta Neuropathol 2002; 104: 425-34.
137. Tolnay M, Spillantini MG, Goedert M, Ulrich J, Langui D, Probst A. Argyrophilic grain disease: widespread hyperphosphorylation of tau protein in limbic neurons. Acta Neuropathol 1997a; 93: 477-84.
138. Tolnay M, Schwietert M, Monsch AU, Staehelin HB, Langui D, Probst A. Argyrophilic grain disease: distribution of grains in patients with and without dementia. Acta Neuropathol 1997b; 94: 353-8.
139. Tsuchiya K, Mitani K, Arai T, Yamada S, Komiya T, Esaki Y, et al. Argyrophilic grain disease mimicking temporal Pick's disease: a clinical, radiological, and pathological study of an autopsy case with a clinical course of 15 years. Acta Neuropathol 2001; 102: 195-9.
140. Uchihara T. Silver diagnosis in neuropathology: principles, practice and revised interpretation. Acta Neuropathol 2007; 113: 483-99.
141. Vadlamudi RK, Joung I, Strominger JL, Shin J. p62, a phosphotyrosine- independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 1996; 271: 20235-7.
142. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, et al. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998; 279: 242-7.
143. van Tijn P, de Vrij FM, Schuurman KG, Dantuma NP, Fischer DF, van Leeuwen FW, et al. Dose-dependent inhibition of the proteasome activity by a mutant ubiquitin associated with neurodegenerative disease. J Cell Sci 2007; 120: 1615-23.
144. Voges D, Zwickl P, Baumeister W. The 26 S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999; 68: 1015-68.
145. Yamada T, McGeer PL. Oligodendroglial microtubular masses: an abnormality observed in some human neurodegenerative diseases. Neurosci Lett 1990; 120: 163-6.
146. Yamada T, McGeer PL, McGeer EG. Some immunohistochemical features of argyrophilic grain dementia with normal cortical choline acetyltransferase but extensive subcortical pathology and markedly reduced dopamine. J Geriatr Psychiatry Neurol 1992; 5: 3-13.
147. Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, et al. p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 2002; 160: 255-63.
148. Zhu X, Lee HG, Casadesus G, Avila J, Drew K, Perry G, et al. Oxidative imbalance in Alzheimer's disease. Mol Neurobiol 2005; 31: 205-17.
149. Zhu X, Raina AK, Lee HG, Chao M, Nunomura A, Tabaton M, et al. Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways. Antioxid Redox Signal 2003; 5: 571-6.
150. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, et al. Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 2001; 76: 435-41.
151. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cyclerelated events in Alzheimer disease. J Neuropathol Exp Neurol 2000; 59: 880-8.
152. Zhukareva V, Shah K, Uryu K, Braak H, Del Tredici K, Sundarraj S, et al. Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer's disease, and Pick's disease. A comparative study. Am J Pathol 2002; 161: 1135-41.
153. Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, et al. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett 2006; 580: 3582-8.